Brightcove Unveils Its New Vision for the Future of Video Engagement, Powered by Proprietary AI and Customer Insight
10.7.2025 10:00:00 CEST | Business Wire | Press Release
Brightcove, the intelligent video engagement company, has today unveiled a bold new chapter in its evolution, signaling a renewed commitment to innovation, customer-centricity and meaningful digital experiences. Backed by new owner Bending Spoons, and incorporating its powerful proprietary AI technology, Brightcove is reimagining its platform to meet the growing demands of both Media and Enterprise customers.
This marks a strategic evolution in how Brightcove approaches product development, balancing cutting-edge innovation with a relentless focus on quality of experience. The company is investing in areas that matter most to its customers, including new AI-powered features developed in-house, enhanced monetization tools, and a more intuitive user experience.
Brightcove’s new direction is the result of extensive collaboration with more than 50 customers across industries, geographies, and use cases. These conversations have shaped a product strategy that is designed to meet the evolving needs of modern video teams while delivering measurable business outcomes.
At the heart of this strategy is a dual focus: Innovation and Quality of Experience. These two tracks will be pursued in parallel to ensure Brightcove continues to deliver meaningful improvements for all customers.
Innovation efforts will:
- Introduce new features, including ultra-HD live streaming, a native recommendations engine, and a pilot for a native webinar and virtual event platform.
- Expand Brightcove’s AI-powered tools, including automated metadata generation, caption generation, translation and audio dubbing in multiple languages, intelligent video clipping and reformatting to optimize for social publishing, and smart content analysis for precise advertising targeting.
Meanwhile, the Quality of Experience track will:
- Refine the core platform through targeted initiatives, such as vertical video support, animated thumbnails, and a comprehensive UX/UI revamp to streamline workflows and enhance usability.
- Implement AI features, like predictive buffering and adaptive bitrate optimization, to help ensure smoother playback across devices and networks.
A key enabler of this transformation is Bending Spoons’ proprietary AI technology. With a proven track record that includes building fully AI-powered products like Remini, as well as integrating AI features into broader platforms such as Evernote and Meetup, Bending Spoons brings deep technical expertise and a vertically integrated stack that accelerates delivery and ensures seamless integration. These capabilities will empower Brightcove to move faster, build smarter, and deliver a more polished experience from day one.
Luca Ferrari, CEO of Bending Spoons, commented: "At Brightcove, our aim is to deliver a powerful and reliable platform that is deeply aligned with the needs of modern media and enterprise users. We're enthusiastic to bring our new product strategy to life, combining customer insight with Bending Spoons' AI expertise to build a long-term strategy hand-in-hand with our customers."
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully.
About Bending Spoons
Bending Spoons has served a billion people across the globe through its suite of digital technology businesses, including Brightcove, Evernote, komoot, Meetup, Remini, StreamYard, and WeTransfer. Its products are currently used by around 300 million people each month.
For more information, visit bendingspoons.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250710991687/en/
Contacts
Brightcove Inc. Media Contact
Rebecca O'Reilly
rebecca.o'reilly@cavendishconsulting.com
Bending Spoons Media Contact
Christy Keenan
ck@bendingspoons.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom